Overview

A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the overall response to a combination of bavituximab and docetaxel in patients with advanced breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
Peregrine Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Bavituximab
Docetaxel